NLS Pharmaceutics AG (NLSPW) - Total Assets
Based on the latest financial reports, NLS Pharmaceutics AG (NLSPW) holds total assets worth $4.34 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NLS Pharmaceutics AG (NLSPW) net assets for net asset value and shareholders' equity analysis.
NLS Pharmaceutics AG - Total Assets Trend (2017–2024)
This chart illustrates how NLS Pharmaceutics AG's total assets have evolved over time, based on quarterly financial data.
NLS Pharmaceutics AG - Asset Composition Analysis
Current Asset Composition (December 2024)
NLS Pharmaceutics AG's total assets of $4.34 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.6% |
| Accounts Receivable | $400.00K | 17.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how NLS Pharmaceutics AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NLS Pharmaceutics AG market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NLS Pharmaceutics AG's current assets represent 99.7% of total assets in 2024, an increase from 99.4% in 2017.
- Cash Position: Cash and equivalents constituted 74.6% of total assets in 2024, down from 95.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 17.9% of total assets.
NLS Pharmaceutics AG Competitors by Total Assets
Key competitors of NLS Pharmaceutics AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
NLS Pharmaceutics AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.77 | 0.15 | 0.45 |
| Quick Ratio | 2.77 | 0.15 | 0.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.58 Million | $-6.53 Million | $-1.60 Million |
NLS Pharmaceutics AG - Advanced Valuation Insights
This section examines the relationship between NLS Pharmaceutics AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 20.9% |
| Total Assets | $2.23 Million |
| Market Capitalization | $169.32 USD |
Valuation Analysis
Below Book Valuation: The market values NLS Pharmaceutics AG's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NLS Pharmaceutics AG's assets grew by 20.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NLS Pharmaceutics AG (2017–2024)
The table below shows the annual total assets of NLS Pharmaceutics AG from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.23 Million | +20.93% |
| 2023-12-31 | $1.85 Million | -80.09% |
| 2022-12-31 | $9.28 Million | +60.92% |
| 2021-12-31 | $5.76 Million | +375.80% |
| 2020-12-31 | $1.21 Million | +73.97% |
| 2019-12-31 | $696.43K | +378.20% |
| 2018-12-31 | $145.63K | -93.64% |
| 2017-12-31 | $2.29 Million | -- |
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more